PT1135158E - Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica - Google Patents

Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica

Info

Publication number
PT1135158E
PT1135158E PT99963705T PT99963705T PT1135158E PT 1135158 E PT1135158 E PT 1135158E PT 99963705 T PT99963705 T PT 99963705T PT 99963705 T PT99963705 T PT 99963705T PT 1135158 E PT1135158 E PT 1135158E
Authority
PT
Portugal
Prior art keywords
immunogenic polypeptides
methods
mammal
ige
nucleic acid
Prior art date
Application number
PT99963705T
Other languages
English (en)
Portuguese (pt)
Inventor
Lars T Hellman
Original Assignee
Resistentia Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals Ab filed Critical Resistentia Pharmaceuticals Ab
Publication of PT1135158E publication Critical patent/PT1135158E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT99963705T 1998-11-02 1999-10-21 Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica PT1135158E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10665298P 1998-11-02 1998-11-02
US09/401,636 US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses

Publications (1)

Publication Number Publication Date
PT1135158E true PT1135158E (pt) 2006-05-31

Family

ID=26803871

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99963705T PT1135158E (pt) 1998-11-02 1999-10-21 Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica

Country Status (17)

Country Link
US (3) US6913749B2 (enExample)
EP (1) EP1135158B1 (enExample)
JP (2) JP4205861B2 (enExample)
KR (1) KR100559918B1 (enExample)
AT (1) ATE314087T1 (enExample)
AU (1) AU771889B2 (enExample)
CA (1) CA2348756A1 (enExample)
DE (1) DE69929240T2 (enExample)
DK (1) DK1135158T3 (enExample)
ES (1) ES2255325T3 (enExample)
HU (1) HUP0105392A3 (enExample)
IL (1) IL142582A0 (enExample)
NO (1) NO20012135L (enExample)
NZ (1) NZ511079A (enExample)
PL (1) PL348611A1 (enExample)
PT (1) PT1135158E (enExample)
WO (1) WO2000025722A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP2065052A3 (en) * 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
EP1330263A2 (en) * 2000-09-06 2003-07-30 Pharmexa A/S Method for down-regulating ige
ES2306771T3 (es) 2001-02-20 2008-11-16 Ortho Mcneil Pharm Inc Un metodo de terapia celular para tratamiento de tumores.
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
ATE438710T1 (de) * 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
WO2003096966A2 (en) * 2002-05-21 2003-11-27 Resistentia Pharmaceuticals Ab Chimeric ige polypeptides and host cells
ES2316780T3 (es) * 2002-09-05 2009-04-16 Resistentia Pharmaceuticals Ab Vacunas contra alergia.
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
BRPI0922561A2 (pt) 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptídeo de ch3 da ige.
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CN104395337A (zh) * 2012-06-18 2015-03-04 日本全药工业株式会社 IgE肽疫苗
JP2019509059A (ja) 2016-02-16 2019-04-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 変異型キヌレニナーゼ遺伝子を有する非ヒト動物
ES3031566T3 (en) 2019-06-24 2025-07-09 Univ Stuttgart Tnfr2 agonists with improved stability

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US5698201A (en) 1973-05-07 1997-12-16 The Ohio State University Method for treatment of antigenically modified polypeptides
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4483793A (en) 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
EP0617127A1 (en) 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Antigenic epitopes on B cell-bound IgE Immunoglobulins
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5955076A (en) 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5733553A (en) 1989-09-29 1998-03-31 Talwar; Gursaran Prasad Recombinant birth control vaccine
DE69126607T2 (de) 1990-01-23 1998-01-15 Tanox Biosystems, Inc., Houston, Tex. Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
JPH05508835A (ja) 1990-05-25 1993-12-09 ペプチド・セラピューティクス・リミテッド 慢性関節リウマチの免疫診断検定法
US5196197A (en) 1990-08-29 1993-03-23 National Institute Of Immunology Reversible fertility control for prevention of pregnancy in females
CA2097291A1 (en) * 1990-12-13 1992-06-14 David P. Gearing Leukemia inhibitory factor receptors
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
US5837686A (en) 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
EP0662085A1 (en) 1992-09-01 1995-07-12 International Centre for Genetic Engineering and Biotechnology Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum
AU5361794A (en) 1992-10-14 1994-05-09 Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
US5762931A (en) 1992-12-31 1998-06-09 National Institute Of Immunology Anti-cancer utility of HCG vaccines
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US5501855A (en) 1993-09-02 1996-03-26 Talwar; Gursaran P. Neem oil as a male contraceptive
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
FR2715304B1 (fr) 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
WO1995026365A1 (en) 1994-03-28 1995-10-05 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
EP0787150A1 (en) 1994-10-25 1997-08-06 United Biomedical, Inc. SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY
GB9422294D0 (en) 1994-11-04 1994-12-21 Peptide Therapeutics Ltd Peptides for anti-allergy treatment
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
DE69633623T2 (de) 1995-07-17 2005-12-01 Medivir Uk Ltd. Cystein-Protease-Inhibitoren für die Behandlung von allergischen Krankheiten verursacht duch IgE
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
TR199801722T2 (xx) 1996-03-01 1998-12-21 Novartis Ag Peptit imm�nojenler.
CA2262001C (en) 1996-08-05 2003-05-20 President And Fellows Of Harvard College Mhc binding peptide oligomers and methods of use
NZ337955A (en) 1997-04-15 2000-09-29 Ferring Farma Lab Modified TNF-alpha and their use as vaccines
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
EP1053343A2 (en) 1998-02-11 2000-11-22 Maxygen, Inc. Targeting of genetic vaccine vectors
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
EE200100552A (et) 1999-04-23 2002-12-16 Pharmexa A/S Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP1330263A2 (en) 2000-09-06 2003-07-30 Pharmexa A/S Method for down-regulating ige
CN1541266A (zh) 2001-06-15 2004-10-27 唐诚公司 用于治疗过敏症及哮喘病的Fcε融合蛋白

Also Published As

Publication number Publication date
PL348611A1 (en) 2002-06-03
ES2255325T3 (es) 2006-06-16
NZ511079A (en) 2003-08-29
JP2006068015A (ja) 2006-03-16
WO2000025722A2 (en) 2000-05-11
IL142582A0 (en) 2002-03-10
HK1042844A1 (en) 2002-08-30
KR100559918B1 (ko) 2006-03-13
US20040076625A1 (en) 2004-04-22
DK1135158T3 (da) 2006-05-15
JP4205861B2 (ja) 2009-01-07
US7459158B2 (en) 2008-12-02
KR20010089364A (ko) 2001-10-06
DE69929240T2 (de) 2006-08-31
NO20012135D0 (no) 2001-04-30
US20010038843A1 (en) 2001-11-08
ATE314087T1 (de) 2006-01-15
DE69929240D1 (de) 2006-02-02
HUP0105392A3 (en) 2008-04-28
AU771889B2 (en) 2004-04-08
NO20012135L (no) 2001-06-25
WO2000025722A3 (en) 2000-10-12
US6913749B2 (en) 2005-07-05
CA2348756A1 (en) 2000-05-11
EP1135158B1 (en) 2005-12-28
JP4188353B2 (ja) 2008-11-26
US20030031663A1 (en) 2003-02-13
AU2008100A (en) 2000-05-22
JP2002531064A (ja) 2002-09-24
HUP0105392A2 (hu) 2002-04-29
EP1135158A2 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
DK1135158T3 (da) Forbedrede vacciner baseret på kimære immunglobulin-E-peptider
NO346167B1 (no) Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DK1798288T3 (da) Humane Toll-lignende receptorproteiner, relaterede reagenser og fremgangsmåder
BR0113112A (pt) Anticorpos, de integrina antidual, composições, métodos e usos
AR052285A1 (es) Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
NO994983L (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
DE602004031017D1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DK0500659T3 (da) Monoklonale antistoffer.
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
BR0009781A (pt) Anticorpos antiidiotìpicos contra anticorpos que inibem a ligação de imunoglobulina e ao seu receptor de alta afinidade
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
EP1621209A3 (en) Vaccines based on domains of chimeric immunoglobulin E peptides
WO2004050111A3 (en) Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
WO2004000238A3 (en) Utilization of mhc class ii binding motifs in immunization to produce immune serum, monoclonal antibodies and vaccines
DE50114032D1 (de) Fusionsprotein zur gleichzeitigen Erkennung von humanen Autoantikörpern
Lou et al. Destruction of zona pellucida of ovulated oocytes by anti-ZP3 antibodies: a potential mechanism of ZP-based contraceptive vaccine
Robert et al. Congenital toxoplasmosis: value of prenatal diagnosis and post-natal follow-up of newborns
CR8389A (es) Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas